GSK and ViiV Showcase Infectious Disease Innovations

GSK and ViiV Healthcare are set to unveil new data at IDWeek 2024 in Los Angeles, focusing on their infectious disease pipeline, which includes 60 abstracts spanning vaccines and treatments for respiratory syncytial virus (RSV), herpes zoster, urinary tract infections, and HIV. Key highlights will include data on their RSV vaccine, Arexvy, and gepotidacin, an investigational antibiotic targeting uUTIs.

The presentations aim to address significant public health challenges, including the rising threat of antimicrobial resistance (AMR). GSK emphasizes its commitment to innovative solutions in prevention and treatment, aiming to enhance global health outcomes.

GSK has a long-standing history of pioneering efforts in infectious diseases, leveraging its diverse portfolio to develop preventative and therapeutic treatments. Their ongoing research and strategic collaborations underscore their dedication to tackling health issues with high unmet needs.